Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OlympiaN phase 2 neoadjuvant olaparib with or without durvalumab in BRCA-mutated HER2-negative early breast cancer
MOH_2022-11-24_012086Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib and durvalumab in breast cancer (2 arms), sponsored by AstraZeneca. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
olaparibdurvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2022-11-24_012086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-24_012086.